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Background: To better understand the relative effects of infection with nontuberculous mycobacteria and Gram negative bacteria on lung function
decline in cystic ﬁbrosis, we assessed the impact of each infection in a Danish setting.
Methods: Longitudinal registry study of 432 patients with cystic ﬁbrosis contributing 53,771 lung function measures between 1974 and 2014. We
used a mixed effects model with longitudinally structured correlation, while adjusting for clinically important covariates.
Results: Infections with a signiﬁcant impact on rate of decline in %FEV1 were Mycobacterium abscessus complex with −2.22% points per year
(95% CI −3.21 to −1.23), Burkholderia cepacia complex −1.95% (95% CI −2.51 to −1.39), Achromobacter xylosoxidans −1.55% (95% CI
−2.21 to −0.90), and Pseudomonas aeruginosa −0.95% (95% CI −1.24 to −0.66). Clearing M. abscessus complex was associated with a change
to a slower decline, similar in magnitude to the pre-infection slope.
Conclusions: In a national population we have demonstrated the impact on lung function of each chronic CF pathogen.M. abscessus complex was
associated with the worst impact on lung function. Eradication of M. abscessus complex may signiﬁcantly improve lung function.
© 2015 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. This is an open access article under the CC BY
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The natural history of CF lung disease is characterized by
chronic progression with intermittent episodes of acute worsen-
ing of symptoms, termed pulmonary exacerbations, often
precipitated by bacterial infections, which become established
within viscid airway secretions. Understanding the distinct
impact of chronic infections in cystic fibrosis (CF) is important,
because lung function decline takes place in a setting of multiple
competing pathogens. Prioritizing treatment starting with the
most serious threat to patients' health is a central challenge for
clinicians. While the impact of major Gram negative infections
have previously been reported [1,2], there are limited data from
population level studies comparing the relative influence of the
major bacterial pathogens.
The principle of always using early, aggressive treatment
aimed at eradication of both Gram positive and negative infection
has been in use since 1976 in Denmark [3,4]. As a consequence
chronic persistent Staphyloccocus aureus infection is infrequent-
ly seen [5]. Methicillin-resistant S. aureus is rare in Denmark in
general and almost non-existent among patients with CF [5].
If eradication therapy for Gram negative bacteria fails,
elective 2-week courses of intravenous chemotherapy are
administered at regular intervals to pre-empt exacerbations
and maintain lung function. Since 1987 inhaled antibiotics have
been a part of the standard treatment of chronic infection with
subsequent additions of continuous dornase alpha and
azithromycin treatment, when these treatments became avail-
able. These principles have been employed for infection due to
Pseudomonas aeruginosa, Achromobacter xylosoxidans and
Burkholderia cepacia complex, which have all been described
to be associated with worse outcomes, including survival, lung
function, and nutritional status [1,6–9]. The significance of
chronic infection with Stenotrophomonas maltophilia and
nontuberculous mycobacteria (NTM) is less clear. Except in
rare cases, S. maltophilia is not treated in Denmark [10], while
NTM is subject to intensive treatment following guidelines
from the American Thoracic Society (ATS) and the Infectious
Disease Society of America (IDSA)'s consensus documents
[11]. Three previous studies of clinical outcomes following
NTM have shown, respectively, no effect, significant effect or a
calamitous effect on expected forced expiratory volume in 1 s
(%FEV1) [12–14]. Understanding the significance of NTM on
lung function in patients with cystic fibrosis (CF) is important,
given the intensive therapeutic regimen required to clear
infection, and associated side effects [11,15].
The aim of the study was to assess and contrast the impacts
of chronic Gram negative infections and NTM on lung function
in patients with CF. Aspergillus infection and Gram positive
bacterial infection were not included in this dataset due to
inherent differences in how chronic infection was defined and
registered for these pathogens.
2. Methods
We undertook a longitudinal analysis of lung function in
Danish patients with CF. All patients born from 1974 onwardswere included if seen at the Copenhagen CF Center; patients seen
at the other Danish CF center in Aarhus, were included from
2002. The pre-1974 birth cohorts were excluded to reduce the
influence of survivor bias as previously described in this dataset
[8]. Post-transplantation data were likewise excluded. Further
methodological details are available in the online appendix.
2.1. Setting
Throughout the study period from 1974 to August 2014,
patients attending the two Danish CF Centers were seen
routinely every month in the outpatient clinic, for evaluation of
clinical status, pulmonary function, and microbiology of lower
respiratory tract secretions. Pulmonary function tests were
performed according to international recommendations [16],
measuring FEV1, expressed as a percentage of predicted values
for sex and height using reference equations from Wang or
Hankinson [17,18].
The hypothesis we wanted to test was that onset of infection
with Mycobacterium abscessus complex (MABSC) and Myco-
bacterium avium complex (MAC) would lead to deterioration of
lung function as previously shown with P. aeruginosa, A.
xylosoxidans, B. cepacia complex and S. maltophilia. The
primary outcome of interest in the statistical model was the
change in slope of %FEV1 at the first time point, at which,
individuals transitioned to fulfill the definition of chronic
infection. Chronic Gram negative infection was defined accord-
ing to modified Leeds criteria (more than 50% positive culture
samples during a year). In Copenhagen, specific precipitating
antibodies were also used to support the definition of chronic
infection as previously described [4,19,20]. For NTM, the term
chronic was not used, but we distinguished between patients who
fulfilled the ATS/IDSA's criteria for NTM pulmonary disease
[11], and those who did not. Onset of NTM infection was defined
as the date of first recorded positive NTM culture. Clearing
infection was defined as consistent culture negativity in N4 NTM
cultures over a minimum of 12 months following cessation of
NTM treatment. Throughout the period, patients were screened
routinely for NTM during bronchoalveolar lavages and when
clinically indicated. Between 1987 and 1988 and again from
2011 onward, all patients with CF in Copenhagen were also
screened annually for NTM with mycobacterial culture.
2.2. Statistical analysis
We developed a longitudinal model for the data using a
previously published approach [8,9]. In brief, we developed a
multivariate longitudinal model to assess the association
between onset (for all infections) and offset of infection (in
the case of MABSC), and slope of lung function trajectory,
while adjusting for birth cohort, genotype (coded as the number
of delta F508 alleles (0, 1 or 2)); pancreatic insufficiency (PI)
(coded 0 or 1 as a baseline covariate); and CF related diabetes
(CFRD) diagnosed using previously published criteria (coded 0
or 1 as a time-varying covariate) [21]. The final model assumed
a linear function for the population-averaged time-trend, though
we explored non-linear approaches, which did not improve
382 T. Qvist et al. / Journal of Cystic Fibrosis 15 (2016) 380–385model fit (Appendix). The longitudinally structured correlation
was modeled as an exponentially decaying function of time
difference (Appendix) [8]. This approach provides a more
realistic estimate of the %FEV1-trend of patients with chronic
lung disease by taking into account the imprecision and
correlation in repeated measurements on the same individual
over time [21]. We assessed the influence of each infection
individually first, and then in a mutually adjusted model
containing all of the infections. We further assessed the effect
of co-infection by adding interaction terms between the infections
to the model. We estimated model parameters by maximum
likelihood, using generalized likelihood ratio statistics to compare
nested models when building the final multivariate model and the
Akaike information criterion (AIC) to compare non-nested
models (when testing for the significance of infection interaction
terms); and Wald statistics to test hypotheses about model
parameters [22]. We visualized the model parameters of interest
by plotting population averaged %FEV1 trajectories with other
model parameters held constant. As a robustness test we repeated
the analysis dropping the earliest birth cohort due to the potential
for survivor effects in the earlier birth cohorts. A level of 0.05 was
set for statistical significance. R version 3.1.1 was used for the
analysis (http://www.R-project.org).
2.3. Ethical considerations
The study was approved by the Danish Data Protection
Agency (file no. 2008-41-2682).
3. Results
3.1. Population characteristics
The dataset contained 53,771 lung function measures on 432
patients who visited the Danish CF centers between 1974 and
2014. The median number of %FEV1 measures per person was
100 (range 1–530). The median follow-up period was 12.3 years
(range 0–35.5), with a total of 9250 person-years of follow-up (see
Appendix for further details). Seventy-six patients were followed
for more than 30 years. The baseline characteristics of the
population, stratified by birth cohort are shown in Table 1.
Genotype and CFRDwere not significant in the final multivariable
model, and were therefore dropped (appendix).Table 1
Characteristics of Danish cystic fibrosis patients by birth cohort.
1974 n (%) 1984 n (%) 1994 n (%) 2004 n (%) Total n (%)
Cohort 120 (27.8) 133 (30.8) 123 (28.5) 56 (13) 432 (100)
Female 62 (51.7) 68 (51.1) 62 (50.4) 31 (55.4) 223 (51.6)
Pancreatic
insufficiency
112 (93.3) 123 (92.5) 120 (97.6) 52 (92.9) 407 (94.2)
P. aeruginosa 82 (68.3) 34 (25.6) 22 (17.9) 3 (5.4) 141 (32.6)
S. maltophilia 14 (11.7) 22 (16.5) 21 (17.1) 5 (8.9) 62 (14.4)
MABSC 10 (8.3) 22 (16.5) 9 (7.3) 3 (5.4) 44 (10.2)
MAC 5 (4.2) 5 (3.8) 4 (3.3) 0 (0) 14 (3.2)
A. xylosoxidans 7 (5.8) 31 (23.3) 1 (0.8) 1 (1.8) 40 (9.3)
B. cepacia
complex
22 (18.3) 13 (9.8) 2 (1.6) 0 (0) 37 (8.6)3.2. Chronic infections
P. aeruginosawas the most common infection, followed by S.
maltophilia, A. xylosoxidans and B. cepacia complex. Eighty-six
(20%) patients developed two chronic infections (Table 2).
Forty-four patients were culture positive for MABSC at least
once; 14 patients hadMAC and two had bothMABSC andMAC
infection. NTM patients contributed a total of 251 NTM positive
person years to the study with a mean NTM positive follow-up
time of 7.6 years. Thirty-nine (70%) patients cleared their NTM
infection.
3.3. Effect of infections on lung function
With the exception of MAC, onset of all infections was
associated with a significant acceleration in %FEV1 decline.
On the basis of the point estimates, after adjustment for
demographic, genetic and clinical factors, MABSC had the
largest effect on lung function; −2.22 percentage points per
annum (95% CI −3.21 to −1.23), followed by the B. cepacia
complex −1.95 (95%CI −2.51 to −1.39), A. xylosoxidans −1.55
(95% CI −2.21 to −0.90), P. aeruginosa −0.95 (95% CI −1.24
to −0.66), and S. maltophilia −0.67 (95% CI −1.21 to −0.13)
(Fig. 1). An overall Wald test confirmed that there were general
significant differences between the effect sizes of the six
infections (p b 0.001). The effect of multiple infections was
checked by adding interactions between the infections to the
model in cases where there were more than 10 people with
co-infection (see Table 2). None of the interaction terms were
significant or improved the model AIC.
Projecting the trend of the negative change in lung function for
each CF pathogen into estimated time to the development of end
stage lung disease, Fig. 2 illustrates the clinical consequence of
each chronic infection. Thus, for a patient born in 1994 and
infected at age 20, all other things being equal, end stage lung
disease will occur after 13.6, 14.7, 16.8, 21.3, 24.4 and 35.6 years
for MABSC, B. cepacia complex, A. xylosoxidans, P. aeruginosa,
S. maltophilia and MAC respectively.
3.4. MABSC and lung function decline
Onset of MABSC was associated with the steepest decline
in lung function decline, but clearance of the infection was
associated with a change to a slower decline, similar inmagnitude
to the pre-infection decline (Fig. 1 and Fig. 3).
3.5. Robustness tests
Repeating the analysis only on data from patients born after
1984 and patients who fulfilled the ATS/IDSA criteria did not
markedly change the results. Tests of the model fit are reported
in the appendix.
4. Discussion
This is the first population level study to simultaneously
compare the effects of different infections on the longitudinal
Table 2
Number of cystic fibrosis patients in Denmark co-infected with Gram negative bacteria or nontuberculous mycobacteria.
P. aeruginosa B. cepacia complex S. maltophilia A. xylosoxidans MABSC(cleared) MAC(cleared)
P. aeruginosa 141 13 18 8 17 (10) 4 (2)
B. cepacia – 37 2 1 0 0
S. maltophilia – – 62 6 15 (5) 4 (2)
A. xylosoxidans – – – 40 6 (0) 3 (3)
MABSC – – – – 44 (20) 2
MAC 14 (8)
MABSC = Mycobacterium abscessus complex, MAC = Mycobacterium avium complex.
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analysis is the visit frequency of examinations (every month)
and long period of follow-up in a complete national population,
facilitating precise estimation of the time of onset of infection.
Furthermore, the frequency of measures of the %FEV1 dataset
allowed a more sophisticated statistical model to be used, which
leads to more robust estimation of the rate of lung function
decline [8]. The order of the negative effects on lung function
was (worst to best): MABSC, B. cepacia complex, A.
xylosoxidans, P. aeruginosa, and S. maltophilia.
4.1. NTM and lung function decline
With 21 years of follow-up of patients with NTM, this study
provides strong evidence for the effects of MABSC and MAC
on lung function in CF. MABSC demonstrated an effect of
−2.2% of excess lung function decline per year; in contrast
MAC infection had no significant effect. Previous studies have
confirmed that MABSC is more virulent than MAC in patients
with CF [11,23,24], but only three studies have looked at effects
on lung function decline in CF. In 2003, Olivier et al. [12]
showed that 18 patients with CF and ATS/IDSA defined NTM
disease did not have a significantly accelerated lung function
decline over a 15-month period. They suggested that a longer
observation time might reveal a difference. In 2010, Esther et al.
[13] examined longitudinal data from 23 patients with MABSCFig. 1. Change in the rate of decline of lung function (%FEV1) following onset
of each infection and clearance of nontuberculous mycobacterial infection. The
point sizes are drawn proportional to the precision of the estimates.and found an excess lung function decline of −0.78% per
year. Martiniano et al. [14] followed 70 MAC and 24
MABSC cases for three years after NTM infection and found
excess annual rates of decline of −4.1% for those who
fulfilled ATS/IDSA criteria, and −1.6% per year for those
with only one positive culture. The authors did not
distinguish between the effects of MABSC and MAC. In
our analysis we did differentiate between the two species,
but interestingly could not find an isolated effect of fulfilling
ATS/IDSA criteria for NTM pulmonary disease. This could
be due to an underestimation of patients who fulfilled the
ATS/IDSA microbiological criteria, either from the early part
of the cohort, where patients were cultured less frequently or
due to the increase in MABSC cases seen in the last year of the
study, where some new cases with clinical deterioration, did
not have sufficient time to fulfill the criteria. Scandinavian
NTM outcomes, including clearance rates have been published
recently [25], with approximately half of ATS/IDSA defined
NTM infected patients achieving culture negativity, typically,
but not exclusively, following extensive treatment. Patients
with MABSC were more likely to develop end stage lungFig. 2. Effect on lung function of chronic infection from onset to end stage lung
disease in Danish cystic fibrosis patients. The figure visualizes the impact of
onset of chronic infections by plotting population averaged %FEV1 trajectories
before and after onset of infection with other model parameters held constant.
Thus for a patient born in 1994 and infected at age 20, all other things being
equal, end stage lung disease will occur after 13.6, 14.7, 16.8, 21.3, 24.4 and
35.6 years for MABSC, B. cepacia complex, A. xylosoxidans, P. aeruginosa, S.
maltophilia and MAC respectively. Footnote: Trajectories plotted and held
constant for a person born in the 1994–2004 birth cohort, mutually adjusted for
other co-variates in the model, with onset of infection occurring at age 20.
Fig. 3. Mean effect on lung function of Mycobacterium abscessus complex
infection from onset and clearance of the infection in Danish patients with CF.
Footnote: Trajectories plotted and held constant for a person born in the 1994–
2004 birth cohorts, mutually adjusted for other co-variates in the model, and
extended beyond the range of the observed data to demonstrate progression to
end stage lung disease.
384 T. Qvist et al. / Journal of Cystic Fibrosis 15 (2016) 380–385disease and the clinical significance of a first positive NTM
culture was high, with almost 3 out of 4 eventually progressing
from a first positive culture to a second [25].
4.2. Effect of clearing MABSC
The observed significant slower decline in lung function
following MABSC clearance (1.9% improvement per year) was
similar to the effect size of acquisition (−2.2% per year). To our
knowledge, this is the first study to suggest that excessive loss
of lung function may be mitigated by MABSC clearance and
our observation of two entirely opposite effects after onset and
clearance of disease give further weight to the notion of a causal
association between MABSC infection and lung function
decline [26].
4.3. Gram negative infection
The observed influence of the different Gram negative
infections on lung function decline is not surprisingly in
accordance with previous independent analyses from the
Danish CF population [10,27–29]. Apart from A. xylosoxidans,
the results are also in accordance with reports from other
countries, which ascribes B. cepacia complex the worst role,
albeit with some inter-species variation [30], followed by P.
aeruginosa, for which there is a larger body of evidence [2,31]
and finally S. maltophilia, which is not considered to be a
serious cause of lung function decline [32,33], although this
perception has been challenged [34]. A. xylosoxidans has been
reported to have either no impact on lung function [35], or an
effect indistinguishable from that of P. aeruginosa [36]. We did
not demonstrate any interaction between infections in terms of
their effects on lung functions, but this finding may reflect
insufficient numbers to detect such effects. The omission of
chronic Gram positive bacteria and Aspergillus infection wasbased on respectively very low prevalence and difficulties in
comparing criteria for chronicity. The issue of whether the
appearance of NTM in CF is the cause of, or alternatively the
consequence of, deteriorating lung function is a key question.
The reverse effect in lung function we observed following
clearance of MABSC is compelling evidence that it is indeed
the mycobacteria causing the deterioration and not the other
way around. Limitations in the study are the retrospective
design and the risk of ascertainment bias which could
underestimate the mitigating effect of asymptomatic MABSC
on the overall MABSC effect. Confounding independent of the
variables we adjust for can likewise not be ruled out.
Differences in how NTM infection and Gram negative infection
are defined and screened for, can be expected to be built into
any CF study since disease criteria and screening recommen-
dations are dissimilar. Our robustness testing however sug-
gested these differences were not important, as the same effect
of MABSC was seen in children infected late in the period and
independently of fulfilling ATS/IDSA criteria. The influence of
survivor bias on lung function estimates in the earlier birth
cohorts is a common problem in datasets of this type [37]. We
handled this by excluding patients born before 1974 [8], where
treatment regimens changed frequently. Repeating the analysis
using only data from more recent cohorts did not alter the
results. Furthermore, fitting the mixed effects longitudinal
model by maximum likelihood implicitly takes this drop out
into account and generates the parameter estimates that one
would expect to see if dropout had not occurred [38,39].4.4. Conclusions
In summary, we have demonstrated the marked effect on
lung function of each Gram negative CF pathogen and NTM,
allowing for the first time, to compare the infections in degrees
of severity. We have shown how MABSC has an important
negative effect on lung function, whereas we did not detect a
significant effect for MAC infection. We observed that clearing
MABSC may restore lung function decline to its previous
slope, pointing to the important role of eradication therapy in
cystic fibrosis.Conﬂict of interest
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